Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BDTX Black Diamond Therapeutics, Inc. daily Stock Chart
BDTX [NASD]
Black Diamond Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.51 Insider Own3.91% Shs Outstand35.91M Perf Week-14.08%
Market Cap1.01B Forward P/E- EPS next Y-2.50 Insider Trans-2.48% Shs Float33.10M Perf Month-11.27%
Income-45.90M PEG- EPS next Q-0.53 Inst Own96.70% Short Float9.21% Perf Quarter-39.00%
Sales- P/S- EPS this Y-294.80% Inst Trans3.98% Short Ratio15.79 Perf Half Y-12.71%
Book/sh9.55 P/B2.82 EPS next Y-18.50% ROA-19.30% Target Price49.25 Perf Year-
Cash/sh5.47 P/C4.92 EPS next 5Y- ROE-30.00% 52W Range17.63 - 46.25 Perf YTD-31.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.79% Beta-
Dividend %- Quick Ratio33.90 Sales past 5Y- Gross Margin- 52W Low52.69% ATR1.93
Employees32 Current Ratio33.90 Sales Q/Q- Oper. Margin- RSI (14)41.73 Volatility7.89% 6.98%
OptionableNo Debt/Eq0.00 EPS Q/Q-7.80% Profit Margin- Rel Volume0.51 Prev Close26.17
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume192.93K Price26.92
Recom1.60 SMA20-7.64% SMA50-8.49% SMA200-18.19% Volume99,201 Change2.87%
May-04-20Initiated H.C. Wainwright Buy $53
Feb-24-20Initiated JP Morgan Overweight $42
Feb-24-20Initiated Jefferies Buy
Feb-24-20Initiated Cowen Outperform
Feb-24-20Initiated Canaccord Genuity Buy $50
Sep-10-20 07:45AM  
Black Diamond Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
GlobeNewswire
Sep-08-20 04:05PM  
Black Diamond Therapeutics Announces the Appointment of Rachel Humphrey, M.D., as Chief Medical Officer
GlobeNewswire
Aug-11-20 07:45AM  
Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire
Aug-10-20 08:42AM  
Is a Surprise Coming for Black Diamond Therapeutics (BDTX) This Earnings Season?
Zacks +8.76%
Aug-05-20 07:45AM  
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
Aug-04-20 07:45AM  
Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer
GlobeNewswire
Jul-30-20 09:58AM  
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Simply Wall St.
Jul-28-20 07:45AM  
Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation
GlobeNewswire
Jun-16-20 07:45AM  
Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
GlobeNewswire
May-27-20 07:45AM  
Black Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference
GlobeNewswire
May-13-20 05:15PM  
Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020
GlobeNewswire
May-12-20 07:45AM  
Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update
GlobeNewswire
May-06-20 07:45AM  
Black Diamond Therapeutics to Present at the Bank of America Global Research Health Care Conference 2020
GlobeNewswire
May-05-20 11:46AM  
3 Biotech Stocks With Plenty of Upside in the Pipeline
TipRanks
Feb-24-20 09:37AM  
Black Diamonds Cancer Drug May Be a Master Key, Street Says
Bloomberg -12.26%
Jan-30-20 04:29PM  
Black Diamond Therapeutics Doubles After $201 Million IPO
Bloomberg
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leggett ThomasChief Financial OfficerSep 14Option Exercise10.863,00032,5803,000Sep 16 06:09 PM
Hatzis-Schoch BrentSee RemarksSep 14Option Exercise3.204,07813,0507,078Sep 16 06:11 PM
Leggett ThomasChief Financial OfficerSep 14Sale31.003,00093,0000Sep 16 06:09 PM
Hatzis-Schoch BrentSee RemarksSep 14Sale31.044,078126,5833,000Sep 16 06:11 PM
Roberts Christopher D.Chief Scientific OfficerSep 03Option Exercise10.862,50027,1502,500Sep 04 05:27 PM
Roberts Christopher D.Chief Scientific OfficerSep 03Sale29.592,50073,9870Sep 04 05:27 PM
Bolzon Bradley J PhDDirectorAug 11Sale33.087,575250,5911,125,778Aug 12 07:46 PM
Versant Venture Capital VI, L.10% OwnerAug 11Sale33.0888329,2111,125,778Aug 12 07:57 PM
Versant Venture Capital VI, L.10% OwnerAug 11Sale33.086,692221,3806,797,230Aug 12 07:57 PM
Versant Venture Capital VI, L.10% OwnerAug 10Sale33.0472523,9531,126,661Aug 12 07:57 PM
Versant Venture Capital VI, L.10% OwnerAug 10Sale33.045,492181,4466,803,922Aug 12 07:57 PM
Bolzon Bradley J PhDDirectorAug 10Sale33.046,217205,3981,126,661Aug 12 07:46 PM
open in yahoo | open in reuters | open in google